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An elevated blood level of homocysteine is an inde-
pendent risk factor for artherosclerosis.1 This can lead
to early onset of coronary artery disease, cerebro-
vascular disease and peripheral vascular disease.2
Clinical evidence is lacking with regard to its role in
acute arterial thrombosis in the absence of underlying
atherosclerosis. We report on a patient with an acute
ischaemic limb secondary to an in situ thrombosis of
the iliac and femoral artery where no atherosclerotic
lesions were identified. Subsequent investigation
revealed that the patient was hyperhomocysteinaemic.
Case Report
A 32-year-old Chinese man presented with a one-day
history of a painful, cold right calf and foot. He gave
no history of recent trauma and had no history of
diabetes, hypertension, hyperlipidaemia or vascular
thrombosis. He had smoked ten cigarettes per day
for the past fourteen years.
On examination, he had a sinus tachycardic
(100 beats/min) but auscultation revealed no cardiac
murmurs and his abdomen was soft with no pulsatile
masses. The right lower limb from the knee down
was pale and cold. His calf was tense and painful on
palpation. No femoral, popliteal or distal pulses were
palpable. The haemoglobin was 14.8 g/dl, white blood
count was 9.13 109/l and platelet count 274 109/l ,
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was 27 s (27.6±39.6). Electrocardiogram showed no
abnormality.
He underwent an exploration of the right femoral
artery through a right groin incision. An arteriotomy
was made over the common femoral artery and fresh
white clots were encountered. A Fogarty embol-
ectomy size 3 catheter was used to retrieve clot
both proximally and distally. This produced good
inflow and an on-table angiogram revealed normal
calibre vessels with good distal runoff. There was
no evidence of atherosclerosis. A four-compartment
fasciotomy was carried out to relieve the compart-
ment syndrome. At the end of the procedure the
femoral dorsalis pedis and posterior tibial artery
pulses were palpable with good capillary refill in the
sole of the foot.
Histology of the clot confirmed thrombus composed
of fibrin alternating with clumps of red blood cells and
inflammatory cells, consistent with a thrombus that
had formed in situ. A 2D echocardiogram showed that
there was no likely source of embolus from the heart
with normal valves and ventricular function. Doppler
ultrasound of the abdominal aorta was normal.
A screen for thrombophilia prior to anticoagulation
treatment revealed that the Protein C was 103%
(70±140%), functional Protein S was 67% (65±140%),
anti-thrombin III was 85% (80±120%), Activated
Protein C (APC) Normalised Ratio was 1.0 (0.9±1.2),
Factor V Leiden was absent by PCR analysis.
Immunological screen for lupus anticoagulant, anti-
cardiolipin Ig M and Ig G, antinuclear antibody,
anti double-stranded DNA antibody was negative.
The plasma homocysteine level was 43.7 mmol/l
(normal 515 mmol/l).rights reserved.
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sequently placed on warfarin before discharge. The
international normalized ratio (INR) was stabilised
at 2.5±3.0 prior to discharge. He was also started on
folate supplementation of 5 mg/day to treat his hyper-
homocysteinaemia. His post-operative course was
uneventful and he was discharged on the 7th post-
operative day. At three months his plasma homo-
cysteine level had returned to normal levels of
7.3 mmol/l and his INR was maintained in the target
range on 3 mg of warfarin. He had also stopped
smoking. He remains well with no further thrombotic
events, at twelve months.
Discussion
Hyperhomocysteinaemia is a metabolic disorder that
results from abnormalities in the function of enzymes
in the methionine metabolism pathway. This is either
a congenital defect or from an acquired deficiency of
vitamins that act as cosubstrates and cofactors like
folate, vitamin B6 or B12. The relationship between
elevated levels of homocysteine and vascular patho-
logy was established by McCully in 1969.3 Young
patients below the age of thirty with severe hyper-
homocysteinaemia are at a high risk of a vascular
event like myocardial infarction and stroke. Adults
that have a mild to moderate increase in homocysteine
levels are at risk of atherosclerotic vascular disease
independent of diabetes, smoking, hypertension and
hyperlipidaemia.4 The pathogenesis of atherosclerosis
caused by hyperhomocysteinaemia involves a com-
bination of endothelial cell damage from oxidative
damage, altered platelet activation and aggregation
and vascular smooth muscle proliferation.
The relationship between hyperhomocysteinaemia
and thrombosis is not clearly demonstrated. Simioni
et al.5 has reported a 2.6 increased risk for deep
vein thrombosis in patients suspected of having
deep-venous thrombosis (DVT). However, this is not
been supported by large meta-analysis and in children
with inherited enzyme deficiency.6 The association
with arterial thrombosis, especially in the absence
of artherosclerosis has rarely been described and is
poorly understood. It is suggested that homocysteine
may promote thrombosis by enhanced tissue factor
expression and factor V activity, suppression of
thrombomodulin activity and decreased fibrinolysis.7
The young age of our patient, together with the
absence of atherosclerosis or proximal embolic
source, and the presence of in-situ thrombus
strongly supports the diagnosis of a hypercoagulableEur J Vasc Endovasc Surg Vol 24, September 2002state as the underlying cause of the acute arterial
thrombosis.
Elevation of the plasma homocysteine was the
only abnormality identified to account for the hyper-
coagulable state in our young patient. Significantly, he
was also a smoker. The interaction of cigarette smok-
ing and elevated levels of homocysteine for develop-
ment of atherosclerotic disease is multiplicative.4 This
similar interaction could have created a pro-thrombotic
milieu in this young man with the resulting con-
sequences. The aetiology underlying the elevated
homocysteine level is likely to be related to low folate
levels. The commonest cause for low folate levels is
related to low dietary intake. Intervention studies
have demonstrated a strong inverse relationship
between homocysteine levels and plasma/dietary
folate levels and decrease in homocysteine levels
after administration of folic acid.2 This decrease
occurs even when subjects had documented normal
levels of folate prior to intervention. In our case, the
patient was started on oral folate supplementation
and his homocysteine levels returned to normal at
follow-up.
This rare case provides clinical evidence to support
the association of hyperhomocysteinaemia and acute
arterial thrombosis. Young patients presenting with
acute thrombosis of large vessels in the absence of an
embolic source or atherosclerotic disease should be
evaluated for abnormalities in homocysteine levels.
This can readily be corrected with vitamin supple-
mentation to prevent future life and limb-threatening
thrombotic events.
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